Navigation Links
Thomson Reuters Spotlights the Impact of Personalized Medicine on Pharmaceutical R&D
Date:12/13/2012

PHILADELPHIA, Dec. 13, 2012 /PRNewswire/ -- The IP & Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced the publication of a new report that provides a comprehensive view of the potential effects of personalized medicine on drug research and development. Spotlight on Personalized Medicine, a Pharma Matters report based on insights and information from Thomson Reuters Cortellis for Competitive Intelligence and a selection of data from CMR International, details the current challenges posed by the paradigm of stratified medicine as well as its clinical, economic and societal value.

"An array of scientific and market factors have prompted the pharma industry to question the sustainability of the current R&D model, which targets large populations with chronic unmet medical needs," said Jon Brett-Harris, executive vice president at Thomson Reuters. "Despite the commercial success of these products, the one-size-fits-all focus has resulted in spiraling R&D costs, longer development timelines and narrow product portfolios. New options, specifically personalized medicine, appear to be an attractive and more sustainable solution. This new report offers a detailed look into the possible advantages and disadvantages of this potentially game-changing approach."

The report shows that a stratified paradigm could result in more efficient ways of conducting drug development, as well as address increased public awareness related to post-marketing withdrawals of popular drugs and debates concerning drug pricing and reimbursement. Further, the ability to better assess biological factors related to disease and therapy at the genetic level lends itself to the development of safer, more effective treatments for specific patient subgroups.

The slow pace of the industry to adopt a more stratified approach has been reinvigorated with high-profile drug launches and successes; however, numerous challenges still exist that could affect a large-scale integration of the personalized medicine paradigm into biopharmaceutical R&D. Analysis from Thomson Reuters Cortellis for Competitive Intelligence suggests a gap in connecting the dots between genetic variation, disease association, patient segments with those variations, clinical trial design and patient recruitment in the clinic.

Thomson Reuters Cortellis, the premier life sciences platform, is the most powerful tool of its kind for biopharmaceutical competitive intelligence, drug pipeline, and drug research and development information. CMR International, a Thomson Reuters business, is the world leader in global pharmaceutical R&D performance measurement. To learn more about Cortellis and CMR International, visit: http://ip-science.thomsonreuters.com/.

Click here to view this Spotlight on Personalized Medicine.

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
2. Thomson Reuters Finds Increase in New Research for Neglected Tropical Diseases
3. Thomson Reuters Speeds Regulatory Decision Making with New Pharmaceutical Intelligence Solution
4. Thomson Reuters Annual Pharmaceutical Factbook Reveals Key Insights into Current Trends
5. Thomson Reuters Welcomes Inova Software to Its Partner Ecosystem for Life Sciences
6. Roche Selects Thomson Reuters to Transform the Management of Its Intellectual Property Assets
7. Thomson Reuters Empowers Drug Development and Clinical Professionals to Develop Better, Faster Clinical Trials with Best-in-Class Intelligence Solution
8. Fujifilm Spotlights DR Expansion, Innovation At RSNA 2012
9. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
10. AdvaMed & BioOhio Discuss MedTech Impact on Ohios Economy, Job Creation
11. CVS Caremark Sponsored Research Finds FDA Drug Warnings Can Have Immediate Negative Impact on Medication Adherence, Even if Not Related to Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... , Dec. 8, 2016 Bodycad announced ... for improving the accuracy, reproducibility and speed for ... long and small bone orthopaedic applications. These patents ... creating personalized orthopaedic restorations based on each patient,s ... restorations, the company harnesses the world,s first suite ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Coppin Insurance Agency, an insurance and financial planning ... the Cape Coral area, is embarking on a charity drive with the goal of ... The Harry Chapin Food Bank of Southwest Florida works to provide fresh and nutritious ...
(Date:12/8/2016)... ... December 08, 2016 , ... Bill Mull Agencies, a ... in and around central Kansas, is joining the Youth Horizons organization for a ... , Headquartered in Wichita, Youth Horizons works to empower area children from unstable, ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA and mental ... mental health systems reform legislation in more than fifty years. We applaud the ... of our elected officials to improving mental health services and supports in our ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is a ... smoothing and tightening the skin of the face to create more youthful features. ... with very little downtime, Silhouette Instalift is a novel, minimally invasive facial procedure ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Technology, S.L. (“Presence”) for a purchase price of approximately $17.4 million (net ... Presence’s annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence ...
Breaking Medicine News(10 mins):